Korea Research Institute of Bioscience and Biotechnology

Dae Gwin Jeong

Seong Eon Ryu

Hwan Mook Kim

Tae Sung Yoon

Seung Jun Kim

Chang Woo Lee

Jin Hee Ahn

Jeong Hee Moon

Song Kyu Park

Ki Ho Lee

Suk Kyeong Jung

Joong-Kwon Choi

Seung-Jun Kim

Dae Sub Song

Seok-II Hong

Jae Hoon Kim

Jeong Hee Son

Sun Woo Yoon

Sang Hyeup Lee

Young Joon Hong

The present invention relates to a versatile influenza virus vaccine composition using the HA2 helical domain of a hemagglutinin protein, which is an influenza surface protein, and to a pharmaceutical composition for preventing or treating influenza virus infectious diseases. The polypeptide expressed by SEQ ID NO: 3 and the polypeptide expressed by residues 379 to 474 of SEQ ID NO: 1 of the present invention can be mass-produced in, and effectively produce neutralizing antibodies to various influenza virus subtypes, and thus the polypeptides can be widely utilized as versatile vaccines for influenza virus subtypes and new influenza virus variants.

Versatile influenza virus vaccine composition

The present invention relates to a method for quantifying protein tyrosine phosphatase (referred as PTP hereinafter) in biosamples, precisely a diagnostic method for disease by quantifying PTP using mass spectrometry and profiling of comparative PTP levels. By quantifying PTP in biosamples and profiling thereof according to the method of the present invention, disease can be diagnosed and diverse disease conditions and health conditions can be confirmed via profiling.

Method for diagnosis of disease using quantitative monitoring of protein tyrosine phosphatase

Disclosed herein are rhodanine derivatives, a method for the preparation thereof, and a pharmaceutical composition containing the same. The rhodanine derivatives have inhibitory activity against protein phosphatases (PPase) such as PTP1B, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PP1 and VHR, and can be applied for the prevention and treatment of PPase-caused diseases, including autoimmune diseases, diabetes, impaired glucose intolerance, insulin resistance, obesity, cancers, etc. when the inhibitory activity thereof is modulated.

Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same

The present invention relates to a crystal structure of PRL-1 (Phospatase of Regenerating Liver) protein and a method of crystallization thereof. It has been found that the PRL-1 protein has a tertiary structure having 5 strands of beta-sheet surrounded by 6 alpha-helices and well-arranged active site with closed P-loop, and monomers form a trimer through farnesylation site in the C-terminus of said protein. Thus intra-cellular migration and membrane localization can be achieved. The said crystal structure of PRL-1 protein of the present invention is very useful for the development the agent which inhibits carcinogenesis and metastasis of the cancer.

Crystal of a phosphatase of regenerating liver 1 (PRL-1) polypeptide and method of crystallization thereof

Growing community of inventors

Daejeon, South Korea

Dae Gwin Jeong